Clinical trial

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT03004105

Study summary

ClinicalTrials.gov

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Selumetinib Normalized identity: selumetinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumab View linked drug · Find medicine records · Find other trials using this name

BEHAVIORAL · Unmapped registry intervention Phone Calls Find medicine records · Find other trials using this name

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2018-05-01

PhasePHASE2

Conditions

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinomaunresolved

Advanced Lung Cancerunresolved

Recurrent Nonsmall Cell Lung Cancerunresolved

Interventions

SelumetinibDRUG · verified · RxNorm: selumetinib

DurvalumabDRUG · verified · RxNorm: durvalumab

Phone CallsBEHAVIORAL

Sponsors & collaborators

M.D. Anderson Cancer Centerlead sponsor

AstraZenecacollaborator

MedImmune LLCcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03004105 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.